If I was a patient I would take a 10% vs 0% shot at MPR and a doubling in DFS. Particularly if adverse events less or comparable. And let’s not forget we have better targeted, more tolerable options now. Strategy totally makes sense but trials and enrollment lag behind. #lcsm
-
-
-
A surgeon arguing to delay surgery? The benefit in any systemic therapy is in decreasing distant mets and no evidence neoadj better than adjuvant. For trials to understand mechanisms neoadj is great. Clinically I don’t see it becoming standard of care.
- Još 4 druga odgovora
Novi razgovor -
-
-
Perfect analysis as usual buddy. I agree with y
-
Thank you Alfredo!! You’re so proactive!!!
Kraj razgovora
Novi razgovor -
-
-
Totally agree.
-
Your feedback is highly valued!! Thanks!!
Kraj razgovora
Novi razgovor -
-
-
Hard to see how such small trial could change clinical practice even if the results were positive. Wonder what would have happened if control arm was radiochemo. Nice work anyway.
-
It's extremely challenging to find stage IIIA-N2 EGFR mutant lung cancer patients, and we have to acknowledge the hard work they did. Not easy to run this trial again.
Kraj razgovora
Novi razgovor -
-
-
What about induction of resistant mechanisms?
-
That’s a very well taken point. We know about that in the metastatic setting. Even with 3rd gen EGFR TKI, new data presented last Friday
#ESMO18 from FLAURA and AURA3. Also in the adjuvant setting, ex20 T790M prevalence varies upon time of progression.https://www.ncbi.nlm.nih.gov/labs/pubmed/21831955-maintained-sensitivity-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutant-lung-cancer-recurring-after-adjuvant-erlotinib-or-gefitinib/?from_term=Oxnard+T790M&from_page=2&from_pos=4 …
Kraj razgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.